Plectin stabilizes microtubules during osteoclastic bone resorption by acting as a scaffold for Src and Pyk2.


Journal

Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048

Informations de publication

Date de publication:
03 2020
Historique:
received: 29 08 2019
revised: 18 12 2019
accepted: 18 12 2019
pubmed: 24 12 2019
medline: 22 6 2021
entrez: 24 12 2019
Statut: ppublish

Résumé

Osteoclasts are multinuclear cells which maintain bone homeostasis by resorbing bone. During bone resorption, osteoclasts attach to the bone matrix via a sealing zone formed by an actin ring. Rous sarcoma oncogene (Src) is essential for actin ring formation and bone resorption. Recently, we demonstrated that plectin, a cytolinker protein, is a Src-binding protein in osteoclasts. However, the function of plectin in osteoclasts remains unknown. In this study, we demonstrated that shRNA knockdown of plectin in RAW 264.7 cells resulted in tartrate resistant acid phosphatase positive multinuclear cells (TRAP (+) MNCs) with impaired actin ring formation and bone resorption activity. Moreover, we found that in plectin-silenced TRAP (+) MNCs, Src and protein tyrosine kinase 2 beta (Pyk2), two critical kinases in osteoclastic bone resorption, were inactivated and microtubule polarity was disturbed. These results suggest that plectin plays a critical role in osteoclast biology by acting as a scaffold to facilitate Src and Pyk2 activation during microtubule organization.

Identifiants

pubmed: 31866495
pii: S8756-3282(19)30505-8
doi: 10.1016/j.bone.2019.115209
pii:
doi:

Substances chimiques

Plectin 0
Focal Adhesion Kinase 2 EC 2.7.10.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115209

Subventions

Organisme : NIAMS NIH HHS
ID : R01 AR042927
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR062054
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Takuma Matsubara (T)

Division of Molecular Signaling and Biochemistry, Department of Health Promotion, Kyushu Dental University, 2-6-1, Manazuru, Kitakyushu, Fukuoka 8038580, Japan. Electronic address: r15matsubara@fa.kyu-dent.ac.jp.

Tatsuki Yaginuma (T)

Division of Molecular Signaling and Biochemistry, Department of Health Promotion, Kyushu Dental University, 2-6-1, Manazuru, Kitakyushu, Fukuoka 8038580, Japan; Division of Oral Medicine, Department of Physical Functions, Kyushu Dental University, Kitakyushu, Japan.

William N Addison (WN)

Division of Molecular Signaling and Biochemistry, Department of Health Promotion, Kyushu Dental University, 2-6-1, Manazuru, Kitakyushu, Fukuoka 8038580, Japan.

Yuko Fujita (Y)

Division of Developmental Stomatognathic Function Science, Department of Health Promotion, Kyushu Dental University, 2-6-1, Manazuru, Kitakyushu, Fukuoka 8038580, Japan.

Kouji Watanabe (K)

Division of Developmental Stomatognathic Function Science, Department of Health Promotion, Kyushu Dental University, 2-6-1, Manazuru, Kitakyushu, Fukuoka 8038580, Japan.

Izumi Yoshioka (I)

Division of Oral Medicine, Department of Physical Functions, Kyushu Dental University, Kitakyushu, Japan.

Hisako Hikiji (H)

School of Oral Health Sciences, Kyushu Dental University, 2-6-1, Manazuru, Kitakyushu, Fukuoka 8038580, Japan.

Kenshi Maki (K)

Division of Developmental Stomatognathic Function Science, Department of Health Promotion, Kyushu Dental University, 2-6-1, Manazuru, Kitakyushu, Fukuoka 8038580, Japan.

Roland Baron (R)

Department of Medicine, Harvard Medical School and Division of Bone and Mineral Research, Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, 188 Longwood Ave., Boston, MA 02115, USA.

Shoichiro Kokabu (S)

Division of Molecular Signaling and Biochemistry, Department of Health Promotion, Kyushu Dental University, 2-6-1, Manazuru, Kitakyushu, Fukuoka 8038580, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH